IDX Integral Diagnostics Ltd
- 2.450
- +0.020+0.82%
Integral Diagnostics Ltd News
Investors in Integral Diagnostics (ASX:IDX) Have Unfortunately Lost 40% Over the Last Three Years
How AI Could Boost This ASX 300 Healthcare Stock
ASX 300 healthcare stock Integral Diagnostics Ltd (ASX: IDX) is up 1.43% to $2.49 per share on Thursday.
While Institutions Own 40% of Integral Diagnostics Limited (ASX:IDX), Retail Investors Are Its Largest Shareholders With 44% Ownership
Capital Allocation Trends At Integral Diagnostics (ASX:IDX) Aren't Ideal
Morgan Stanley Adjusts Integral Diagnostics' Price Target to AU$1.85 From AU$1.70, Keeps at Underweight
09:05 PM EST, 03/05/2024 (MT Newswires) -- Morgan Stanley Adjusts Integral Diagnostics' Price Target to AU$1.85 From AU$1.70, Keeps at Underweight Price (AUD): $2.23, Change: $-0.06, Percent Change:
Integral Diagnostics Price Target Raised 13% to A$2.20/Share by Citi
Integral Diagnostics Price Target Raised 13% to A$2.20/Share by Citi
Integral Diagnostics Target Price Raised 8% to A$2.65/Share by Macquarie>IDX.AU
Integral Diagnostics Target Price Raised 8% to A$2.65/Share by Macquarie>IDX.AU
Integral Diagnostics Price Target Raised 4% to A$2.60/Share by Ord Minnett
Integral Diagnostics Price Target Raised 4% to A$2.60/Share by Ord Minnett
Integral Diagnostics Posts 7% Rise in H1 FY24 Revenue, Profit Slips
Integral Diagnostics Ltd. (ASX:IDX) reported Tuesday that its operating diluted earnings per share in the six-month period ended Dec. 31, 2023 was AU$0.031, compared with the prior-year period's AU$0.
Integral Diagnostics Expects FY 2024 Replacement, Growth Capex of A$30 Million-A$40 Million
Integral Diagnostics Expects FY 2024 Replacement, Growth Capex of A$30 Million-A$40 Million
Integral Diagnostics Revenue Up 12% in 2H So Far
Integral Diagnostics Revenue Up 12% in 2H So Far
Integral Diagnostics Expects 2H Operating Ebitda Margin in Line or Slightly Better Than 1H
Integral Diagnostics Expects 2H Operating Ebitda Margin in Line or Slightly Better Than 1H
Integral Diagnostics 1H Net Loss A$66.8 Million
Integral Diagnostics 1H Net Loss A$66.8 Million
Medicare Levy Change: 1.2 Million Aussies to Get Extra Tax Boost
Millions of Aussies will be able to avoid or pay a lower Medicare levy under a major change announced by the government.
Australia's Q4 Inflation Rate Eases to 0.6%, Falling Below Expectations
The CPI slowed to 0.6% in the December quarter, down from 1.2% in the previous quarter. Market consensus was 0.8%.
Integral Diagnostics Price Target Cut 3.9% to A$2.45/Share by Macquarie
Integral Diagnostics Price Target Cut 3.9% to A$2.45/Share by Macquarie
Australian Inflation Slows in November to 4.3%, Below Forecast
The headline consumer price index increased by 4.3% over the 12 months to November, down from 4.9% in October. This figure came in just below the market forecast of 4.4%.
When Can ASX 200 Investors Expect RBA Interest Rate Cuts?
Will interest rates go higher yet from here? Or can ASX 200 investors look forward to some rate-cutting relief from the RBA in 2024?
Australian Flash PMI Data Shows Economy on Track For a Soft Landing
Australian private sector business activity continued to contract in December as demand conditions remained soft, but the data still points to a soft landing for the commodity-
Australia's GDP Expands 0.2% in Q3, Below Forecasts
Australia’s gross domestic product grew 0.2% in the third quarter, from 0.4% in Q2, undershooting the market consensus of 0.4%.
Analysis
Price Target
No Data
